Glaxosmithkline Plc: (NYSE: GSK)
$52.73
-0.21 (-0.40%)
Volume 1,418,701
May 23 04:02 PM ET
Zacks Rank: 3-Hold 
| #3 |
Overview Quote
Stock Activity
| Day Low - High | 52.30 - 52.86 |
| 52wk Low - High | 41.68 - 53.45 |
| Previous Close | 52.94 |
| Avg. Volume | 2,299,012 |
| Industry | LARGE CAP PHARMA |
| Market Cap | 129.81 B |
| Div - Yield | 2.20 - 4.16 |
| Beta | 0.64 |
| PE (Forward) | 14.53 |
| Current Year Est. | 3.64 |
| Quarterly Earnings ESP |
0.00% |
Premium research
Zacks Rank
|
 3 |
Zacks Recommendation
|
Neutral |
Zacks Industry Rank
|
171 out of 265 |
Equity Research Report
|
PREMIUM |
( = Change in last 30 days)
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial
Key Earnings Data
| PE (Forward) | 14.53 |
| PEG Ratio | 2.19 |
| Current Year Est. | 3.64 |
| Current Quarter Estimate | 0.88 |
| Most Accurate Estimate | 0.88 |
| Earnings ESP |
0.00% |
| Next Earnings Report Date | 07-24-2013 |
| EPS Last Year | 3.53 |
| Expected Earnings Growth | 6.62% |
Company Description
GlaxoSmithKline is one of the world's leading research based pharmaceutical and healthcare companies and is committed to improving the quality of human life by enabling people to do more, feel better and live longer. They also have leadership in four major therapeutic areas: anti-infectives, central nervous system (CNS), respiratory and gastro-intestinal/metabolic.
NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.
Turn Earnings Surprises into quick profits.
Earnings Estimates
| Current Qtr (06/2013) |
Next Qtr (09/2013) |
Current Year (12/2013) |
Next Year (12/2014) |
|
|---|---|---|---|---|
| Average Estimate | 0.88 | 0.91 | 3.64 | 4.02 |
| Number of Estimates | 2 | 2 | 7 | 6 |
| Low Estimate | 0.88 | 0.88 | 3.60 | 3.78 |
| High Estimate | 0.89 | 0.93 | 3.79 | NA |
| Year Ago EPS | 0.82 | 0.85 | 3.58 | 3.64 |
| EPS Growth | 7.93% | 6.47% | 1.76% | 10.26% |
Industry Analysis
| Name | Symbol | Previous Close | Zacks Rank | Zacks Recommendation |
|---|---|---|---|---|
| GLAXOSMITHKLINE | GSK | 52.94 | |
|
| ABBOTT LABS | ABT | 37.72 | |
|
| ABBVIE INC | ABBV | 46.76 | |
|
| ALLERGAN INC | AGN | 97.73 | |
|
| ASTRAZENECA PLC | AZN | 52.35 | |
|
| BAYER A G -ADR | BAYRY | 109.20 | |
|
| BRISTOL-MYERS | BMY | 46.40 | |
|
| JOHNSON & JOHNS | JNJ | 88.46 | |
|
| LILLY ELI & CO | LLY | 54.92 | |
|
| MERCK & CO INC | MRK | 46.71 | |
|
Sector:Medical>> Industry:LARGE CAP PHARMA
COMPARE TICKER vs. Its Peers
Zacks Commentary
Data on UCB's Neupro
May 22, 2013
XenoPort Resumes Horizant Supply
May 22, 2013
XenoPort Candidate Disappoints
May 21, 2013
Elan Provides Strategic Update
May 21, 2013
Elan in Royalty Deal with THRX
May 14, 2013
Wider-than-Expected Loss at ChemoCentryx
May 14, 2013
Glaxo/THRX's Breo Ellipta Gets FDA Nod
May 13, 2013
Isis Reports In-Line Loss
May 08, 2013
Financials
| EPS TTM | 3.53 |
| Sales | 41,896 |
| Net Income | 6,624 |
| Price/Earnings | 15.00 |
| Price/Book | 10.97 |
| Price/Cash Flow | 12.37 |
| Price/Sales | 3.14 |
News
German, French Indices Vulnerable at Elevated Levels - TheMotleyFool
May 23, 2013
Glaxo unit to work on public-private antibiotics research - Mcclatchy-Tribune Information Services -- Unrestricted
May 23, 2013
GlaxoSmithKline Begins Discovery Fast Track Competition for Academic Researchers - Close-Up Media
May 23, 2013
Research and Markets Adds Report: GlaxoSmithKline Partnering 2005-2013 - Close-Up Media
May 23, 2013
3 Reasons to Love GlaxoSmithKline - TheMotleyFool
May 22, 2013
Glaxo to develop new antibiotics - Mcclatchy-Tribune News Service
May 22, 2013
GlaxoSmithKline awarded up to $200 million by U.S. government to develop new antibiotics - M2
May 22, 2013
GlaxoSmithKline to axe 120 jobs at Melbourne site - Abix
May 22, 2013
Broker Recommendations
| Current ABR | 3.00 |
| ABR (Last Week) | 3.00 |
| # of recs in ABR | 10 |
| Average Target Price | 49.69 |
| Industry Rank by ABR | 171 out of 265 |
| Rank in Industry | 1 out of 15 |
